Shareholder Tools

Press Releases

Press Releases
Date Title and Summary View
Mar 2, 2015 Dose Escalation Continues for EC1456 and EC1169 as Endocyte Outlines Plans for Expansion of the Trials in Targeted Patients Once Maximum Doses Are Determined Conference Call Today at 8:30 a.m. EST WEST LAFAYETTE, Ind., March 2, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug...
Feb 27, 2015 WEST LAFAYETTE, Ind., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from ongoing phase 1 trials of Endocyte's SMD...
Feb 23, 2015 WEST LAFAYETTE, Ind., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Monday, March 2, at 8:30 a.m. EST to discuss its fourth quarter and full year 2014 financial results and provide an operational update. Investors and the general public are invited to listen t...
Feb 17, 2015 WEST LAFAYETTE, Ind., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the following upcoming healthcare conferences. 2015 RBC Capital...
Nov 5, 2014 Folate-targeted EC1456 with Potent Tubulysin Payload Now at Higher Phase 1 Dose Level than Vintafolide Conference Call Today at 4:30 p.m. EST WEST LAFAYETTE, Ind., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for pe...
Nov 4, 2014 WEST LAFAYETTE, Ind., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman, chief financial and operating officer of Endocyte, will present at the 2014 Credit Suisse Healthcare Con...
Oct 29, 2014 WEST LAFAYETTE, Ind., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2014 financial results and provide an operational update. Investors and the general public are invited to listen to a live webc...
Sep 27, 2014 - Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid - - Interim Update of Overall Survival Analysis Shows 30 Percent Reduction of Risk of Death in Pre-Defined Adenocarcinoma Patient Subgroup - - Conference Call/Webcast at 8:30 a.m. EDT Monday, Sept. 29 - WEST LAFAYET...
Sep 22, 2014 WEST LAFAYETTE, Ind., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented at the European Society for Medical Oncology (ESMO) Conference on Saturday, S...
Aug 27, 2014 WEST LAFAYETTE, Ind., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Baird 2014 Health Care Conference on Wednesday, Sept. 3, at 2:20 p....
1
... NextLast
Add to Briefcase = add release to Briefcase